Literature DB >> 14566465

[Membranous glomerulonephritis].

S Scheidat1, R A K Stahl.   

Abstract

Membranous nephropathy remains the most common cause of nephrotic syndrome in adults. The common variant is idiopathic membranous nephropathy with no evidence of any known precipitating factors. Membranous nephropathy also occurs as a secondary form in association with inflammatory or neoplastic diseases. Prognosis is mostly favorable as shown by the frequency of spontaneous remissions which averages 30%, although about one-third of patients progress to end-stage renal failure. Risk factors for a poor prognosis include severe proteinuria, hypertension, older age, male gender and impaired renal function. Therapy should include an ACE-Inhibitor and/or angiotensin-II receptor blocker to lower proteinuria (blood pressure < or =130/80 mmHg). The majority of patients should be observed for six months whilst receiving conservative treatment before deciding about an immunosuppressive approach. The debate over its management continues today. Steroids alone are ineffective. Evidence-based medicine supports the use of cyclosporine or the Ponticelli regimen (monthly cycling routine of chlorambucil or cyclophosphamide alternating with prednisone).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566465     DOI: 10.1007/s00108-003-1022-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  47 in total

1.  New insights into the pathogenesis of proteinuria.

Authors:  R J Johnson
Journal:  Am J Kidney Dis       Date:  2000-07       Impact factor: 8.860

Review 2.  The nephrotic syndrome.

Authors:  S R Orth; E Ritz
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

3.  The evolution of membranous glomerulonephritis reconsidered: new insights from a study on relapsing disease.

Authors:  T Törnroth; E Honkanen; E Pettersson
Journal:  Clin Nephrol       Date:  1987-09       Impact factor: 0.975

Review 4.  Thrombosis and hemostasis in renal disease.

Authors:  T J Rabelink; J J Zwaginga; H A Koomans; J J Sixma
Journal:  Kidney Int       Date:  1994-08       Impact factor: 10.612

5.  Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.

Authors:  Alvaro Torres; Beatriz Domínguez-Gil; Agustín Carreño; Eduardo Hernández; Enrique Morales; Julian Segura; Ester González; Manuel Praga
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

Review 6.  Treatment of membranous nephropathy.

Authors:  C Ponticelli; P Passerini
Journal:  Nephrol Dial Transplant       Date:  2001       Impact factor: 5.992

7.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

8.  IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies.

Authors:  M Haas
Journal:  Am J Kidney Dis       Date:  1994-03       Impact factor: 8.860

9.  Demonstration of a passive Heymann nephritis-like mechanism in a human kidney transplant.

Authors:  M Zanetti; C Mandet; A Duboust; J Bedrossian; J Bariety
Journal:  Clin Nephrol       Date:  1981-05       Impact factor: 0.975

10.  Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.

Authors:  Martin Haas; Gert Mayer; Gerhard Wirnsberger; Herwig Holzer; Manfred Ratschek; Ullrich Neyer; Josef Neuweiler; Reinhard Kramar; Brigitte Schneider; Silvana Breiteneder-Geleff; Heinrich M Regele; Walter H Hörl; Dontscho Kerjaschki
Journal:  Wien Klin Wochenschr       Date:  2002-02-28       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.